

## INDEX

- Absorbed dose, 229
- Absorbed dose meter, 230
- Accidents. *See* Medical response in peacetime nuclear accidents
- ACH. *See* Acetylcholine
- Acetylcholine (ACH), 126
- Acquired immune deficiency syndrome (AIDS), 182
- Active vaccination
  - in the immunosuppressed, 79
- Acute radiation syndrome (ARS), 13, 15-33
  - pathophysiological subsyndromes of, 16-21
  - prodromal stage of (*see* Prodromal stage of ARS)
- Adenine, 197
- Addresses, 275
- AET. *See* Aminoethylisothiuronium
- AFRRI (Armed Forces Radiobiology Research Institute)
  - address, 275
- Age
  - effect of, on cancer risk after radiation exposure, 184-185
- AIDS. *See* Acquired immune deficiency syndrome
- Alginates, 62
- Alkalosis, 49
- Alopecia, 177
- Alpha particles, 8, 21-23, 229-230, 246
- Alpha radiation, 229-230
- Aminoethylisothiuronium (AET), 263
- Aminothiols, 250-255, 257
  - derivative of, 250-254
  - mercaptopropionylglycine (MPG), 251, 255
- Amphetamines
  - and locomotor hyperactivity after irradiation, 133
- Amylase, 86-87, 92
- Anesthesia and pain control, 48
- Ankylosing spondylitis, 188
- Anorexia, 27
  - and gamma radiation, 86
- Antibiotics, 27-28, 75-78
  - broad-spectrum, 81
  - potential synergy between, and radioprotectants, 265-266
- Antidiarrheals. *See* Antiemetics and antidiarrheals
- Antiemetics and antidiarrheals, 48-49, 133
- Antihistamine
  - in radioprotection, and behavior, 132
- Antioncogenes, 183

- Antioxidants
  - naturally occurring, as radioprotection, 250, 255-256
- Arrhythmias, 42
- ARS. *See* Acute radiation syndrome
- Aspermia, 90, 175
  - duration, 175
  - latency, 175
  - recovery, 175
  - see also* Somatic radiation effects, sterility, in males
- Ataxia telangiectasia, 182, 202
  - and its effect on skin radiosensitivity, 177
- Atmospheric testing, 173-174
  - see also* Fallout
- Atom, 2-3
- Attentional focusing, 160
  
- Bacillus Calmette-Guérin* (BCG), 259
- Background radiation, 172-173
  - from consumer products, 174
  - from extraterrestrial radiation
    - cosmic radiation, 172-173
    - solar-flare radiation, 172-173
  - from fallout, 173-174
  - from medical procedures, 172
  - sources
    - potassium-40, 173
    - sodium-24, 173
    - thorium-232, 173, 174
  - see also* Radon gas
- Barium sulfate, 62
- BCG. *See* *Bacillus Calmette-Guérin*
- Becquerel (Bq), 228
- Behavioral changes in irradiated animals
  - cognitive performance, 108-109
  - learning and memory, 107-108
  - motor performance, 109
  - naturalistic behaviors
    - consumption, 111
    - curiosity and investigatory behaviors, 110-111
    - locomotion, 110
    - social behavior, 111
    - taste aversions, 111-112
- Beta burn, 177
  - in atomic-bomb survivors and Marshall Islanders, 177
  - threshold radiation dose of various isotopes, 177-178
  - see also* Somatic radiation effects, on skin and hair

- Beta-carotene, 256
- Beta-mercaptoethylamine (MEA), 263
- Beta particles, 8, 21-23, 229
- Beta radiation, 229
  - and lymphocytes, 94
  - shielding, 229
  - and skin injury, 42
- Biofilms, 69-70
- Biological dosimetry, 86
  - see also* Blood serum dosimeters, Chromosomal dosimeters, Dosimeters, Hematological dosimeters, *and* Urinary Dosimeters
- Biological mediators
  - as altered by radiation, 181
- Blast, 2
  - LD<sub>50</sub> of, 6
- Blast effects, 4-7
  - blast wave, 6-7
  - blast wind, 6-7
  - protection from, 6-7
- Blast injuries, 6
  - triage of, 46
- Blast wave. *See* Blast effects
- Blast wind. *See* Blast effects
- Blocking and diluting agents, 63
- Blood component therapy, 49-50
- Blood serum dosimeters, 91-92
  - diamine oxidase (DAO), 91-92
    - animal response, 91
    - with combined injuries, 92
  - plasma haptoglobin, 92
  - plasma hemoglobin, 92
  - serum alkaline phosphatase in rats, 92
  - serum amylase, 86, 90, 91
    - lack of animal model, 91
    - and parotid gland exposure, 91
  - serum lactate dehydrogenase, 92
  - see also* Dosimeters
- Bloom's syndrome, 182, 202
- Bone-marrow transplantation, 50, 75, 86
  - behavioral benefits of, 134
  - in Chernobyl, USSR, 11, 259
  - military practicality of, 134
  - versus autologous and/or syngeneic transplant, 29
  - see also* Radioprotection
- Bq. *See* Becquerel
- Breast cancer, 184, 193-195

- latency, 193
  - and radiation induction, 193
    - age dependence, 193
- Bremsstrahlung, 5, 9, 117
- Burn injuries
  - flame burns, 7
  - flash burns, 7
  - full-thickness, 79
  - LD<sub>50</sub> for, 7
  - partial-thickness, 79
  - prophylactic management of, 79
  - protection from, 7
  - triage of, 46
  - see also* Eye injuries, Thermal effects
- Cancer, 179-197
  - bone, 184
  - Burkitt's lymphoma, 183, 184
  - colon, 182
  - incidence of, 182
  - intestinal, 184
  - laryngeal, 184
  - liver, 184
  - lung, 172, 182, 184, 194-197
  - myeloid leukemia, chronic, 184
  - myeloma, 182
  - prostate, 182
  - reproductive system, 197
    - and gender differences in incidence, 182
  - stomach, 182, 184
  - T-cell leukemia, 184
  - see also* Breast cancer, Digestive system cancers, Genetic syndromes
    - associated with cancer susceptibility, Leukemia, Ovarian cancer,
    - Respiratory system cancers, Thyroid cancer
- Cancer formation stages
  - initiation, 180-181
  - latency, 180-181
  - promotion, 180-182
  - see also* Models for predicting cancer incidence
- Cancer induction, 179-184
  - and radiation dose, 184
- Cancer promoters, 180-182
  - environmental agents, 182
  - hormones, 181, 192
- Carbon-14. *See* Fallout *and* Radioisotopes
- Carboxypenicillin, 78

- Carcinogenic agents and groups, 181
  - as listed by the National Toxicology Program, 181
- Case shock, 5, 9
- CAT. *See* Computed axial tomography
- Catalase, 255
- Cataracts. *See* Somatic radiation effects, cataract formation
- Ceftazidime, 75
- Central venous catheters
  - for fluid and electrolyte therapy, 49
- Cesium-137. *See* Fallout *and* Radioisotopes
- Chelating agents, 63
  - deferoxamine (DFOA), 63
  - diethylenetriaminepentaacetic acid (DTPA), 50, 62, 63
    - dose, 50, 63
    - as investigational new drug (IND), 63
    - and renal damage, 63
  - dimercaprol, 63
  - ethylenediaminetetraacetic acid (EDTA), 50, 63
    - contraindications, 50
    - dose, 50
  - penicillamine, 63
- "Chemical casualty" in sign language, 46-47
- Chernobyl, USSR, nuclear plant accident at, 10-11, 27, 46, 71, 90, 128, 238-239, 259
- Chromosomal aberrations, 184, 188
  - with acute lymphocytic leukemia, 188
  - with chronic myelogenous leukemia, 188
  - radiation induced, 197, 200
  - and X chromosome, 199
  - see also* Antioncogenes, Genetic radiation effects, Oncogenes, Proto-oncogenes
- Chromosomal dosimeters
  - cultured peripheral blood lymphocyte technique, 94-95
    - problems with, 94-95
    - and radiation dose and type, 94
  - micronuclei technique, 94, 96
    - and control values, 96
    - and bone-marrow transplant cells, 96
  - premature condensed chromosome (PCC) technique, 94, 95-96
    - and standardized kit, 96
    - and time required, 96
  - see also* Dosimeters
- Ci.** *See* Curie
- Cisplatin
  - and WR-2721, 250
- Clavulanic acid, 75

- Clearance time, 56
- Clinical-support therapy  
effect of, on LD<sub>50</sub> dose-effect curve, 27-28
- Cobalt-60  
primate survival after irradiation, 259
- Cockayne's syndrome, 202
- Codon, 197
- Combined injuries, 14  
animal studies, 25-26, 27, 112  
and dosimetry problems, 97-98  
in Japan, 27  
*see also* Management of combined-injury casualties *and*  
Triage of patients with combined injuries
- Computed axial tomography (CAT), 122
- Conditioned taste aversion (CTA), 111
- Cord factor. *See* Trehalose dimycolate
- Corynebacterium parvum*, 259
- Cosmic radiation. *See* Extraterrestrial radiation
- Creatine, 92
- Critical period  
for teratogenic radiation effects, 206
- CTA. *See* Conditioned taste aversion
- Cultured peripheral blood lymphocyte technique, 94-95
- Curie (Ci), 228
- Cyclophosphamide, 181  
and WR-2721, 250
- Cysteine, 263
- Cytokines, 259, 261-263, 267  
erythropoietin, 261  
granulocyte-macrophage colony-stimulating factor (GM-CSF), 50, 261-262  
interferons, 261  
interleukin-1 through interleukin-6, 261-263  
tumor necrosis factor (TNF), 252, 261-263  
*see also* Recombinant leukocyte stimulatory factors
- Cytosine, 197
- Daniels, J., 2
- DAO. *See* Blood serum dosimeters, diamine oxidase
- Day After, The*, 156
- Dazopride (5-HT<sub>3</sub>-receptor Mocker)  
as an antiemetic, 133
- Debridement, 48, 57, 62, 69, 70, 79, 241
- Deferoxamine (DFOA), 63
- Delayed fallout, 9
- Denial, 157
- Deoxyribonucleic acid (DNA), 12

- bases of, 197
- damage to, and cell death, 246, 248
- see also* Genetic syndromes associated with susceptibility to cancer
- Desquamating lesions, wet and dry, 42, 178-179
- Determinants of psychological dysfunction in conventional warfare
  - battle duration, 154
    - for the British (World War II), 154
    - in European theater (World War II), 154
  - battle intensity, 154
    - in Sicilian campaign (World War II), 154
  - communication, 155
  - consequences of incapacitation, 155
    - for Germans at Stalingrad (World War II), 155
  - cultural expectations, 155
    - in Korean War, 155
    - in Vietnam War, 155
    - in World War II (in Arakan campaign, Burma), 155
  - group characteristics, 154
    - among Israelis in Yom Kippur War, 154
  - physical strain, 154-155
- Deuterium, 4
- Dexamethasone
  - in managing emesis, 133
- DFOA. *See* Deferoxamine
- Diabetes
  - and its effect on skin radiosensitivity, 177
- Diamine oxidase (DAO), 91-92
  - see also* Radiation exposure, biological indicators
- Diethylenetriaminepentaacetic acid (DTPA), 50, 62, 63
- Digestive system cancers, 194
  - and Thorotrast induction, 194
- Diluting agents. *See* Blocking and diluting agents
- Disintegrations per minute (dpm), 228
- District of Columbia, 157
- dl-alpha-tocopherol. *See* Vitamin E
- DNA (Defense Nuclear Agency)
  - address, 275
- DNA. *See* Deoxyribonucleic acid
- Dose reduction factor (DRF), 250
- Dose-response curve, 23
  - modification of, 24
- Dosimeters, 86-98, 164, 231
  - fluorometric immunoassay, 97
    - of MN antigens, 97
  - individual military, wristwatch-sized, 164
  - problems with, 97-98

- radiophotoluminescent (RPL) dosimeters, 231
- thermoluminescent dosimeters (TLD), 231
- whole-body radionuclide determination, 97
  - iodine-131, 97
  - sodium-24, 97
- see also* Blood serum dosimeters, Chromosomal dosimeters, Hematological dosimeters, Radiation detection and measurement, *and* Urinary dosimeters
- Dosimetry
  - in Chernobyl, USSR, 10
- Double pulse
  - of thermal output, 5, 7
- Doubling dose
  - of radiation, 202
- Down's syndrome, 200, 202
- dpm. *See* Disintegrations per minute
- DRF. *See* Dose reduction factor
- DTPA. *See* Diethylenetriaminepentaacetic acid
  
- $E = mc^2$ , defined, 3
- Early fallout, 9
- Early performance decrement (EPD), 113, 116, 117, 126, 128
- Early transient incapacitation (ETI), 13, 42, 113
  - ameliorated by WR-1607, 133, 253
  - and shielding, 133-134
- Edison, Thomas, 179
- EDTA. *See* Ethylenediaminetetraacetic acid
- EEG. *See* Radiogenic neuropathology, in electroencephalograph (EEG) recordings
- Eicosanoids, 250, 256
- Electrolytes, 49
- Electrophysiology
  - radiation-induced changes, 124-125
- Emesis, 111-112
  - induced by WR-1607, 133
  - induced by WR-2721, 250
- Emetics, 62
- Endorphins, 127
- Endotoxin, 70, 259-260
- Enhanced radiation weapon. *See* Neutron bomb
- Environmental carcinogens. *See* Cancer promoters, environmental agents
- Enzymatic detoxification, 249-250, 255-256
- Enzymes, 256
- EPD. *See* Early performance decrement
- Epilation, 86, 177, 179
- EPSP. *See* Excitatory postsynaptic potential
- Erythema, 41, 86, 178-179

- see also* Radiation injury, cutaneous phenomena; Skin damage;  
*and* Skin erythema dose (SED), defined
- Erythrocytes, 50, 90
- Erythropoietin, 261
- Estrogens, 133
- Ethiofos. *See* WR-2721
- Ethylenediaminetetraacetic acid (EDTA), 50, 63
- ETI. *See* Early transient incapacitation
- EUCOM. *See* U.S. European Command (EUCOM)  
Chernobyl Task Force
- Excitatory postsynaptic potential (EPSP), 125
- Exothermic process, 2
- Exposure geometry, 24-25, 26, 28-29
- Exposure meter, 230
- Extraterrestrial radiation, 172-173
  - cosmic radiation, 172-173
  - and* radioprotection, 134
  - solar-flare radiation, 172-173
- Eye injuries
  - at Chernobyl, USSR, 46
  - and* combatants, 46
  - corneal edema, 175
  - flash blindness, 7
  - foveal damage, 46
  - lacrimal gland atrophy, 175
  - occupational radiation exposure limit, 175
  - protection from, 7
  - retinal burn, 7
  - triage of, 46
  - see also* Neurophysiology of performance decrements  
*and* Somatic radiation effects, cataract formation
- Fallout, 4, 9-10, 173-174
  - from carbon-14, 173-174
  - from cesium-137, 173
  - from strontium-90, 173
  - see also* Radiation hazards in patient treatment *and* Radioisotopes
- Fallout decay
  - estimating, 235-236
  - predicting hazards, 10
- Fallout shelters
  - dozer trench, 236
  - dug-in mobile hospital tents, 236
  - operation of, 236
  - vehicle-earth shelter, 236
- Fanconi's anemia, 182, 202

- Federal Emergency Management Agency (FEMA), 239
  - address, 275
- FEMA. *See* Federal Emergency Management Agency
- Fibronectin, 72-73
- Fission, defined, 4
- Fission fragments, 4
  - see also* Radioisotopes
- Fission weapons
  - fuel, 4
    - plutonium-239, 4
    - uranium-233, 4
    - uranium-235, 4
  - gun-assembled device, 4
  - implosion device, 4
- Fluorometric immunoassay, 97
- Follicle stimulating hormone (FSH), 176
- Forward therapy, 164
  - Israeli experiences with, 164
- Free-radical scavenging, 249-251, 255-256, 257
- Free radicals, 172, 246-248, 257
- FSH. *See* Follicle stimulating hormone
- Fusion, 4
  - see also* Radioisotopes
- Fusion weapons, 4
  - see also* Radioisotopes
  
- Gamma radiation, 59, 172, 229
  - acute doses of, 86
  - and blood cell effects, 90
  - and lymphocyte count, 87, 89, 94
  - median doses of, for ARS symptoms, 86
  - shielding, 229, 236
  - and skin injury, 41-42
- Gamma rays, 4, 8-9, 13, 21, 246
- Gardner's syndrome, 182
- Gastrointestinal subsyndrome, 13-14, 18-19
  - and nutritional support, 50-51
- Geiger-Mueller (GM) counters, 59, 230
- Genetic approaches to radioprotection, 248, 250, 256, 257
- Genetic radiation effects, 197-205
  - estimating risks, 202-205
  - gene mutations, 197-200
    - factors affecting mutation, 200-202
- Genetic syndromes associated with susceptibility to cancer, 182
  - ataxia telangiectasia, 182, 202
  - Bloom's syndrome, 182, 202

- Fanconi's anemia, 182, 202
- Gardner's syndrome, 182
- Li-Fraumeni's syndrome, 182, 184
- xeroderma pigmentosum, 182, 202
- Genetically significant dose (GSD), 202
- Glasgow coma scale, 38
- Glucan, 252, 258, 260-261, 264, 266
- Glutathione, 263
- Glutathione peroxidase, 255
- Glycine, 92
- GM. *See* Geiger-Mueller (GM) counters
- GM-CSF. *See* Granulocyte-macrophage colony-stimulating factor
- Goggles, lead-lanthanum-zirconium-titanium, 7
- Goiânia, Brazil, radiation accident at, 29, 41, 56, 62
- Gonadotropin, 176
- Gram-negative organisms, 68, 70-72, 74, 77-79
- Gram-positive organisms, 68, 70, 71, 77, 78
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 50, 260, 262
- Granulocytes, 50, 90
- Granulocytopenia, 72
- Gray (Gy), defined, 172, 229
- "Ground zero," 157
- GSD. *See* Genetically significant dose
- Guanine, 197
- Guidelines for medical advisors, 240
- Gun-assembled device, 4
- Gy. *See* Gray (Gy), defined
  
- Half-life, defined, 228
- Haloperidol, 126
- Haptoglobin, 92
- Healthy worker effect, 191
- Hematological dosimeters, 42-43, 87-90
  - in Chernobyl, USSR, 90
  - erythrocytes, 90
  - granulocytes, 90
  - latency, 90
  - lymphocytes, 87-88, 89
  - platelets, 90
  - reticulocytes, 90
  - see also* Blood serum dosimeters, Dosimeters
- Hematopoietic depression, 27, 90
- Hematopoietic precursor cells, 90
  - see also* Stem cells
- Hematopoietic subsyndrome, 13, 16-18, 90
  - and burn injury, 46

- infection in, 71
- Hematopoietic stem cells, 263
  - regeneration of, 257-263
  - shielding of, 28
- Hemoglobin, 92
- Hemorrhage, 90
- Hemorrhagic coagulopathies, 42
- High-LET radiation, 21, 246
  - and radioprotection, 248
  - and teratogenic effects, 208
- Histamine, 19, 41, 92, 126, 127, 135, 172
- HIV. *See* Human immunodeficiency virus
- Human immunodeficiency virus (HIV), 182
- Huntington's chorea, 199
- Hybridoma technology, 79
- Hydrocephaly, 210
- Hydroxyproline, 92
- Hyperthermia, 42
- Hypocalcemia, induced by WR-2721, 250
- Hypoglycemia, 42
- Hypokalemia, 42, 49
- Hyponatremia, 49
- Hypotension, 42
- Hypoxemia, 42
- Hypoxia
  - induction of, as radioprotection, 249, 250
  
- ICRP. *See* International Commission on Radiological Protection
- IL-1. *See* Interleukin-1
- IL-3. *See* Interleukin-3
- Immunoglobulin, 48, 73, 79
- Immunomodulators, 259-261
- Immunosuppression, 72-73
  - and malnutrition, 50
  - in Chernobyl victims, 27
  - by radiation in cancer latency, 181
- Impaired inflammatory response, 72-73
- Implosion device, 4
- IND (investigational new drug), 63
- Infection, 67-81
  - contributors to, 79
  - control of, 48
    - with glucan, 260-261
    - as limiting factor in treatment, 27
  - in Chernobyl, 71

- in hematopoietic subsyndrome, 71
- see also* Infection management
- Infection management, 75-80
  - antibiotics, 75-78
  - supportive therapy, 76-79
  - surgery, 79-80
  - see also* Antibiotics
- Infections associated with radiation injury, 71-72
  - predisposing factors, 72-75
  - see also* Opportunistic infections
- Infectious agents. *See* Pathogens
- Inhibitory postsynaptic potential (IPSP), 125
- Initial nuclear radiation, 4, 5
  - effects of, 7-10
- Initial Response Force (IRF), 239
- Integrating meter, 230
- Interferons, 261
- Interleukin-1 (IL-1), 252, 260, 261-263, 264
- Interleukin-3 (IL-3), 262
- Internal decontamination, 55-64
  - clearing the gastrointestinal tract, 62
    - alginates, 62
    - aluminum antacids, 62
    - barium sulfate, 62
    - emetics, 62
    - ion exchangers, 62
    - phytates, 62
    - purgatives and laxatives, 62
    - stomach lavage, 62
  - preventing or reversing radiobiological interaction, 63
    - blocking and diluting agents, 63
    - chelating agents, 63
    - lung lavage, 63
    - mobilizing agents, 63
  - see also* Chelating agents
- Internal radionuclide contamination, 55-64
  - clearance time, 56
  - ingestion, 56-57
  - inhalation, 56-57
    - model for evaluating hazards of, 56
  - percutaneous absorption, 56
  - wound contamination, 56-57
- International Atomic Energy Agency (IAEA), 95
  - address, 275
- International Commission on Radiological Protection (ICRP), 56, 175, 202

- Ion exchangers, 62
- Ionization, 229
- Ionization chambers, 59, 230
  - pocket dosimeter, 230
- Ionizing radiation, 246
- IPSP. *See* Inhibitory postsynaptic potential
- IRF. *See* Initial Response Force
- Irradiation
  - synergy, with open wound, 79
  
- Kiloton (kt), 4
  - see also* Megaton
- kt. *See* Kiloton.
  
- Lactate dehydrogenase, 86, 87
- Laxatives and purgatives, 62
- LD<sub>50</sub> (lethal dose, or fatal injury, for 50 percent of cases), 6, 23
  - and dependence on dose rate, 31
  - establishing, of radiation for humans, 29-30
    - in air, 29
    - to bone marrow, 29, 33
    - data sources for, 29-30
  - and exposure geometry, 24-25, 26
  - in Hiroshima, 32
    - for humans, 31-33
    - for low-LET radiation, 31-33
  - and radiation quality, 24-25
  - and trauma, 25-27
- Lead-lanthanum-zirconium-titanium goggles, 7
- LET. *See* Linear energy transfer
- Lethality curve, 23-24
- Leukemia, 182, 184, 188-191
- Leukotriene C<sub>4</sub> (LTC<sub>4</sub>), 252, 256
- Li-Fraumeni's syndrome, 182, 184
- Linear energy transfer (LET), 21
- Lipopolysaccharide (LPS) cell-wall component, 70
  - see also* Endotoxin
- Los Alamos, NM, radiation accident at, (Mr. K.), 127-128
- Low-LET radiation, 21, 177, 246
  - and radioprotection, 248
- LPS. *See* Lipopolysaccharide (LPS) cell-wall component
- LTC<sub>4</sub>. *See* Leukotriene C
- Lung cancer, 172, 182, 184, 194-197
- Lung lavage, 63
- Luteinizing hormone, 176
- Lymphocytes, 87-90, 261

- count as a biological dosimeter, 87-90
- nomogram, 42-43,
- Lymphoma
  - Burkitt's, 183, 184
- Macrophages, 72, 261, 262
- Mafenide acetate (sulfamylon), 79
- Management of combined-injury casualties, 46-52
  - anesthesia and pain control, 48
  - antiemetics and antidiarrheals, 48-49
    - atropine, 49
    - diphenoxylate HCl, 49
    - codeine, 49
    - hydrocortisone enemas, 49
    - serotonin (5-HT<sub>3</sub>) blocking agents, 48-49
  - blood component therapy, 49-50
    - anemia and, 49
    - and autologous platelets, 49
    - and erythrocytes, 50
    - and granulocytes, 50
  - chelation therapy, 50
  - fluids and electrolytes, 49
  - infection control, 48
  - nutritional support, 50-51
  - surgery, 47-48
  - see also* Chelating agents
- Management of contaminated patients
  - hospital management, 57-59
  - initial care, resuscitation, and admission, 241
  - on-site management, 57
    - in combined nuclear-chemical war, 57
  - operating-room care, 242
    - patient decontamination, 60-63, 234-235
    - rescue and evacuation in a nuclear accident, 240
    - sampling radioactivity, 57
    - supply checklist, 58
    - treatment decisions, 60
    - uptake and clearance, 56-57
  - see also* Internal radionuclide contamination
- Management of mass casualties, 232-233
  - combined injuries, 232
  - command radiation guidance, 232-233
  - logistical support, 232
  - psychological stress, 232
  - public health, 232
- Manhattan Project, 2

- MAO. *See* Monoamine oxidase
- Marshall Islanders, effects of radiation on, 177-178, 179, 192, 193
- Mass defect, 3
- Maturation-depletion, 90
- MEA. *See* Beta-mercaptoethylamine
- Medical advisor guidelines, 240
- Medical Radiobiology Advisory Team (MRAT), 240  
address, 275
- Medical response in peacetime nuclear accidents  
information demand, 237  
*see also*  
Chernobyl, USSR, nuclear power plant accident at;  
Goiania, Brazil, radiation accident at;  
Los Alamos, NM, radiation accident at (Mr. K.);  
Oak Ridge, TN, radiation accident at;  
Palomares, Spain, nuclear accident at;  
Providence, RI, radiation accident at (Mr. P.);  
Three Mile Island, nuclear power plant, accident at;  
Thule Air Force Base, Greenland, accident at;  
*and* Vinca, Yugoslavia, radiation accident at
- Megaton (MT), 4  
*see also* Kiloton
- Menopause  
induced by radiation, 193
- Menstrual cycle  
effect of radiation on, 177
- Mercaptopropionylglycine (MPG), 251, 255
- Metoclopramide (5-HT<sub>3</sub>-receptor blocker)  
as antiemetic, 133
- MFP. *See* Mixed fission products
- Microbes  
population changes, 73-75
- Microcephaly, 207, 209
- Micronuclei technique, 94, 96
- Military operations in fallout, 235-236
- Military performance  
radiation-induced changes, 129-132
- Military response to nuclear accident or incident  
Initial Response Force (IRF), 239  
On-Scene Commander (OSC), 239-240  
Service Response Force (SRF), 239
- Mixed-fission products (MFP), 60
- Mobilizing agents, 63
- Models for predicting cancer incidence, 184-187  
and leukemia incidence among Nagasaki survivors, 184-187  
linear, 184-187

- linear-quadratic, 184, 187
- pure quadratic with cell killing, 184, 187
- quadratic, 184, 187
- Monoamine oxidase (MAO), 126
- Monoclonal antibodies, 79
- Morphine, 127
- Mortality
  - radiation-induced, 90
  - reduced by radioprotectants, 133
- MPG. *See* Mercaptopropionylglycine
- MRAT. *See* Medical Radiobiology Advisory Team
  
- n-decylaminoethanethiosulfuric acid (WR-1607), 133
  - see also* WRAIR sulfur compounds
- Naloxone, 127
- NATO Standardization Agreement (STANAG 2083), 233
- Nausea, 42
  - gamma radiation dose for, 86
  - induced by WR-2721, 250
- Necrosis, 41, 42, 48, 62, 120, 121, 123, 175, 178, 179, 214, 261
- Neoplasm, 180
  - see also* Cancer
- Neurochemistry
  - radiation-induced changes, 125-126
- Neurological changes induced by radiation, 105-135
- Neuropathological changes *See* Radiogenic neuropathology
- Neurophysiology of performance decrements
  - audition and vestibular function, 120-121
  - olfactory function, 121
  - gustatory function, 121
  - vision, 119-120
- Neuropsychiatric casualties
  - prediction of, 163-164
- Neurotransmitters, 126
- Neurovascular subsyndrome, 13, 14, 19-21
- Neutron bomb, 4
- Neutron particles, 3, 4, 8-9, 13, 229, 230, 246
- Neutron radiation, 229, 230
  - and biological effects, 211
  - shielding, 230
- Nitrogen mustard, 181
- Nondisjunction, 200
- NTIS (National Technical Information Service)
  - address, 275
- nts. *See* Nuclear transformations per second
- "Nuclear casualty" in sign language, 46-47

- Nuclear energy, 2-5
  - kinetic energy, 2
  - potential energy, 2
- Nuclear transformations per second (nts), 228
- Nuclear weapons
  - nuclear and physical processes, 2-5
- Nuclear Weapons Accident Checklists, 243
- Nutritional support
  - of combined-injury casualties, 50-51
- Nystatin, 78
  
- Oak Ridge, TN, radiation accident at, 30
- OCLC (Online Computer Library Center)
  - address, 275
- On-Scene Commander (OSC), 239-240
- Oncogenes, 183-184
- Opiates
  - in radioprotection, and behavior, 132
- Opportunistic infections, 68-71
  - pathogens, 79
- OSC. *See* On-Scene Commander
- Ovarian cancer, 197
- Ovaries
  - radiosensitivity, 176-177
  - see also* Somatic radiation effects, sterility, in females
  
- PAF *See* Platelet-activating factor
- Palomares, Spain, nuclear accident at, 327
- Pathogens
  - Bacteroides*, 68
  - Clostridium*, 68, 69
  - Enterobacter*, 68
  - Escherichia*, 68, 73
  - Klebsiella*, 68, 73
  - Pseudomonas*, 68, 69
  - Staphylococcus*, 68, 70, 73
  - Streptococcus*, 68
- Pathophysiological subsyndrome stages
  - latent, 16
  - manifest illness, 16
  - prodromal, 16
  - recovery, 16
- Patient management
  - principles of, 81
- PCC. *See* Premature condensed chromosome (PCC) technique
- Peacetime radiation accidents. *See* Medical response in peacetime nuclear

- accidents
- Pefloxacin, 266
- Performance decrements, 113-118
  - mitigating, through radioprotection, 132-134, 264
  - and radiation dose, 115-116
  - and radiation dose rate, 116, 118
  - and radiation quality, 117
  - role of CNS in, 133-134
  - and task complexity, 113-115
- Philadelphia chromosome, 184, 188
  - see also* Chromosomal aberrations
- Phosphorothioates, 253, 254
- Photon, 229
- Physical dosimeters. *See* Dosimeters
- Physiological mediators, 247, 249
- Phytates, 62
- Plasma
  - of ions and electrons, 5, 6
- Platelet-activating factor (PAF), 252, 256
- Plateletpheresis, 49
- Platelets, 49, 90
- Plutonium. *See* Fission weapons, fuel, plutonium-239
- Pneumonitis, 42
- Polydactyly, 206
- Post-traumatic stress disorder (PTSD), 161-162
- Postirradiation infections. *See* Infections
- Premature condensed chromosome (PCC) technique, 94, 95-96
- Prodromal stage of ARS, 16, 17, 86
  - dose-dependent latent stage of, 86
  - duration and severity, 86, 88
  - onset and latency, 86, 88
  - symptoms, 86, 88
- Proportional counters, 59, 230
- Prostaglandin inhibitors
  - to minimize skin damage, 178
- Prostaglandins, 92, 172, 256
  - 16, 16-dimethyl prostaglandin E<sub>2</sub> (DiPGE<sub>2</sub>), 252, 256, 264
- Proto-oncogenes, 183, 184
- Protons, 3
- Providence, RI, radiation accident at (Mr. P.), 128
- Prussian blue, 62
- Psychic numbing, 157, 159
- Psychological casualties
  - care of, 164-165
    - and morale, 165
    - and uncertainty about personal injury, 164

- differences in nuclear warfare versus
  - conventional warfare, 155-156
    - description by Hiroshima survivor, 155-156
    - after Three Mile Island accident, 156
    - in U.S. Strategic Bombing Survey, 156
  - prediction of, and military performance, 163-164
  - prevention of, 165-166
  - and self-preservation, 165
  - and social cohesion, 166
  - training recommendations, 165-166
  - in World War II, 154
  - in Yom Kippur War, 154, 166
  - see also* Determinants of psychological dysfunction in conventional warfare
- Psychological changes (acute)
  - fear and terror, 160
    - from U.S. Strategic Bombing Survey, 160
  - in learning and memory, 161
    - absence of conditioned response in animals, 161
    - in Hiroshima survivors, 161
    - retrograde amnesia in animals, 161
    - from Soviet literature, 161
  - in motivation, 158-160
    - in animals, to receive brain stimulation, 158
    - in animals, of curiosity and attention, 158-159
    - in Hiroshima and Nagasaki, 159-160
  - in social relations, 160-161
    - attention to leaders, 160
    - maintenance of social structure, 160-161
- Psychological effects of nuclear warfare. *See* Psychological changes (acute) *and* Psychological reactions (chronic)
- Psychological reactions (chronic)
- Psychological factors in nuclear warfare, 153-166
- Psychological reactions (chronic)
  - anxiety and phobias, 162
    - in Hiroshima, 162
    - and rumors, 162
  - latency of, 161
  - neuroses, 161
    - in Japan, 161
  - post-traumatic stress disorder (PTSD), 161-162
    - after natural disasters, 161-162
    - depression in, 162
    - diagnostic criteria, 162
    - principal features, 162
  - psychoses, 161
    - temporary, among new combat units, 161
  - psychosomatic symptoms, 163

- survivor guilt, 162-163
- PTSD. *See* Post-traumatic stress disorder
- Purgatives and laxatives, 62
  
- QBC 11 assay methodology, 43
- Quinolones, 75
  
- R. *See* Roentgens (R), defined
- R-meter, 230
- Rad, defined, 172, 229
- Radiation, 2, 228
- "Radiation casualty" in sign language, 46
- Radiation counter, 230
- Radiation detection and measurement, 59-60, 230-231
  - Geiger-Mueller (GM) counters, 59, 230
  - film badges, 60
  - ionization chambers, 59, 230
  - proportional counters, 59, 230
  - radiophotoluminescent (RPL) dosimeters, 231
  - scintillation counters, 59, 230-231
  - surface monitoring, 59
  - thermoluminescent dosimeters (TLD), 60, 231
  - see also* Dosimeters
- Radiation dose, 115-116, 230
  - and cancer induction, 184
  - doubling, 202
  - and performance decrement, 115-116
- Radiation dose rate, 116, 184
  - and performance decrement, 116, 118
- Radiation Emergency Assistance Center/Training Site (REAC/TS), Oak Ridge, TN, 63, 240
  - address, 275
- Radiation exposure
  - accidents, 30-31
  - biological indicators, 86, 87
  - case histories, 127-128
  - data sources on, 189
  - regulatory guides, 212-213
  - required to damage organs, 175-187
  - units of measure, 172 (*see also* Gray, Rad, Rem, Roentgens, Sievert)
- Radiation Exposure Status (RES) category system, 233
- Radiation hazards in patient treatment, 234
  - beta-contact, 234
  - internal, 234
  - whole-body gamma radiation, 234
  - see also* Management of contaminated patients *and* Medical advisor

- guidelines
- Radiation injury, 12-13
  - cardiovascular, respiratory, metabolic, and neurological phenomena, 42
    - arrhythmias, 42
    - early transient incapacitation (ETI), 42
    - hemorrhagic coagulopathies, 42
    - hyperthermia, 42
    - hypoglycemia, 42
    - hypotension, 42
    - pneumonitis, 42
  - cutaneous phenomena, 41-42
    - erythema, 41
    - melanotic pigmentation, 41
    - necrosis, 41
    - skin sensations, 41
    - ulceration, 41
  - gastrointestinal phenomena, 42
    - in combined chemical-nuclear environments, 42
    - diarrhea, 42
    - nausea and vomiting, 42
  - hematological phenomena, 42-43
    - and blood cell morphology, 42-43
    - and lymphocyte nomogram, 42-44
  - symptoms of, 40-41
  - see also* Beta burn, Skin damage, Somatic radiation effects on skin and hair
- Radiation quality, 12, 24-25, 117
  - and cancer induction, 184
  - and performance decrement, 117
- Radioactive material, 228
- Radioactivity, 228
- Radiogenic neuropathology, 122-124, 157, 158-163
  - of beta-endorphin, 158
  - cerebral ischemia, 123
  - cortex, 122
  - data from Japan, 157
  - demyelination, 121, 123
  - of dopamine metabolism, 158
  - dorsal medulla, 122
  - in electroencephalograph (EEG) recordings, 158
  - glial cells, 123
  - hippocampus, 123
  - hypothalamus, 122
  - morphology, 122
  - necrosis, 121, 123
  - optic chiasm, 122
- Radioisotopes, 4, 173-174

- and chelation therapy, 50
- treatment of contamination by, 60-61
- see also* Dosimeters, Whole-body radionuclide determination,  
and Management of contaminated patients
- Radiological Advisory Medical Team (RAMT), 240
- address, 275
- Radiolysis
- products of, 172
- water, 250
- Radiomimetic agents, 181
- cyclophosphamide, 181
- nitrogen mustard, 181
- Radionuclide contamination. *See* Internal radionuclide contamination
- Radiophotoluminescent (RPL) dosimeters, 231
- see also* Dosimeters and Radiation detection and measurement
- Radioprotection, 245-269
- and behavior, 132-134
- in space, 134
- and supportive therapy, 264-266
- see also* Antiemetics and antidiarrheals, Radioprotective agents,  
Radioprotective strategies, Shielding
- Radioprotective agents
- aminothiols, 250-255, 257
- combination agents, 263-266
- cytokines, 259, 261-263
- of detoxification, 252, 255
- eicosanoids, 250, 256
- genetic approaches, 250, 256
- naturally occurring antioxidants, 250, 255-256
- of regeneration, 252, 257-263
- Radioprotective regimen requirements, 266-268
- deliverability, 267-268
- effectiveness, 266-267
- toxicity, 267
- Radioprotective strategies
- protection, 248-256
- free radical scavenging, 249-250
- hypoxia, 249
- regeneration, 248, 257-263
- repair, 248, 257
- genetic, 257
- hydrogen transfer, 257
- Radiotherapy, 29-30
- Radon gas, 172
- daughter products
- polonium-214, 172

- polonium-218, 172
  - radon-220, 172
  - radon-222, 172
- RAMT. *See* Radiological Advisory Medical Team
- Ratemeter, 230
- RBE. *See* Relative biological effectiveness
- REAC/TS. *See* Radiation Emergency Assistance Center/  
Training Site (REAC/TS), Oak Ridge, TN
- Reciprocal translocation, 200
- Recombinant granulocyte-macrophage colony-stimulating factor, 260
- Recombinant leukocyte stimulatory factors, 50
- Relative biological effectiveness (RBE), 25
- Rem, 172
- Rem-meter, 230
- RES. *See* Radiation Exposure Status (RES) category system
- RES. *See* Reticuloendothelial system
- Residual radiation, 5, 7-10, 236
  - effects of, 7-10
  - estimating decay of, 236
- Respiratory system cancers, 172, 182, 184, 194-197
- Reticulocytes, 90
- Reticuloendothelial system (RES), 72
- Retrograde amnesia, 107
- Ribonucleic acid (RNA), 200
- RNA. *See* Ribonucleic acid
- Roentgen, Wilhelm Conrad, 2, 177
- Roentgens (R), defined, 172
- RPL. *See* Radiophotoluminescent (RPL) dosimeters
  
- Salting, 9
- Scintillation counters, 59, 230-231
- SED. *See* Skin erythema dose
- Segmented filamentous microflora (SFM), 74
- Selenium
  - as radioprotectant, 252, 255, 256, 264
  - to reduce toxicity of WR-2721, 256
- Serotonin
  - as radioprotective agent, 263
- Serum amylase, 86, 87, 90, 91
- Service Response Force (SRF), 239
- SFM. *See* Segmented filamentous microflora
- "Shell shock" syndrome, 164
- Shielding, 28-29, 133-134, 235-236, 267
  - see also* Radioprotection
- Sievert (Sv), defined, 172
- Sign language

- for "chemical casualty," 46-47
- for "radiation casualty," 46-47
- Silvadene. *See* Silver sulfadiazine
- Silver sulfadiazine (silvadene), 79
- Skin damage, 177-179
  - beta burn, 178
  - cancer, 178-179
  - epilation, 179
  - erythema, 178-179
    - neutron radiation threshold, 178
  - fibrosis, 179
  - fingernail pigmentation, 179
    - in Marshall Islanders, 179
  - hyperpigmentation, 179
  - hypopigmentation, 179
  - necrosis, 178-179
  - and radiation dose, 178
  - telangiectasia, 179
  - transepithelial injury (moist desquamation), 178-179
  - ulceration, 178-179
  - see also* Beta burn, Erythema
- Skin decontamination, 48, 60-62
- Skin erythema dose (SED), defined, 177
  - exposure proposed for radiologists, 177
  - of X radiation, 177
- Somatic cell fusion (hybridoma technology), 79
- Somatic radiation effects, 175-187
  - cataract formation, 175
    - among Nagasaki survivors, 175
    - incidence, 175, 176
    - latency, 175
    - radiation threshold, 175
  - on skin and hair, 177-179
    - as affected by disease, 177
    - alopecia, 177
    - from alpha radiation, 177
    - dermatitis, 177
    - epilation, 177, 179
    - see also* Beta burn, Skin damage
  - sterility, 175-177
    - in females, 176-177
    - in males, 175-176
  - see also* Cancer induction
- Spina bifida, 210
- SRF. *See* Service Response Force
- STANAG. *See* NATO Standardization Agreement (STANAG 2083)

- Stem cells
  - bone marrow, 25, 90
  - depletion of, 248
  - hematopoietic, 25, 28, 90, 263
    - mitotic delay or destruction of, 90
  - regeneration, capability of, 28
  - stromal, 90
  - survival of, increased, 263
- Stem formation, 9
- Sterility, 175-177
- Steroids
  - and managing emesis, 133
- Stomach lavage, 62
- Strong force, 3
- Strontium-90. *See* Fallout *and* Radioisotopes
- Stunting, 208
- Sulfamylon. *See* Mafenide acetate
- Sulfhydryls, 253, 254
- Superoxide dismutase, 252, 255, 256
- Surgery, 47-48, 79
  - and antibiotics, 79
  - timing of, after irradiation, 79
- Sv. *See* Sievert
- Symptoms of irradiation, 88
  
- T-cell leukemia, 184
- T-cells
  - activation of, by interleukin-1, 261
  - in AIDS, 182
  - T-4 lymphocytes, 182
- Taurine, 92
- TDM. *See* Trehalose dimycolate
- Teenagers
  - survey of, on likelihood of nuclear war, 156
- Telangiectasia, 179
- Television dramatization. *See* Day After, The
- Teratogenic radiation effects, 205-211
  - embryonic developmental stages, 205
    - fetal, 205, 208
    - major organogenesis, 205, 206-208
    - preimplantation, 205, 206
  - humans irradiated *in utero*, 209-211
    - and fetal mortality, 209
    - and greater cancer incidence, 211
    - in Hiroshima, 207
- Testes

- radiosensitivity, 175
  - see also* Somatic radiation effects, sterility, in males
- Testosterone, 176
- Therapeutic index, defined, 250
- Thermal effects, 7
  - production of, 4-5
- Thermal force, 2
- Thermoluminescent dosimeters (TLD), 60, 231
  - see also* Dosimeters and Radiation detection and measurement
- Thiola. *See* Mercaptopropionylglycine
- Thiosulfonates, 253, 254
- Thorotrast, 189
- Three Mile Island, PA, nuclear power plant accident at, 156
- Thule Air Force Base, Greenland, accident at, 238
- Thymine, 197
- Thyroid cancer, 182, 184, 185, 191-193
  - and ethnic groups, 192
  - prevalence in women, 191-193
  - and thyroid irradiation, 193
- TLD. *See* Thermoluminescent dosimeters
- TNF. *See* Tumor-necrosis factor
- Trauma, influence of,
  - on LD<sub>50</sub>, 25-27
- Trehalose dimycolate (TDM), 252, 260-261, 265
- Triage, 11, 37-46
  - of blast injury, 46
  - of burn injury, 46
  - of eye injury, 46
  - military, 40
  - of patients with combined injuries, 43-46
    - and radiation dose, 40, 45
  - in peacetime, 39-40
  - priority categories, 38-39
    - delayed treatment, 38
    - expectant, 38
    - immediate treatment, 38
    - minimal treatment, 38
- Trinity device, 4
- Tritium, 4
- Tumor-necrosis factor (TNF), 252, 261-263, 264
- Turner's syndrome, 206
  
- Ulceration, 41, 178-179
- Uranium. *See* Fission weapons, fuel, uranium-233 and uranium-235
- Urinary dosimeters, 87, 92
  - amylase, 87, 92

- creatine, 87, 92
- glycine, 92
- hindrances to development, 92
- histamine, 87, 92
- hydroxyproline, 92
- prostaglandins, 87, 92
- taurine, 87, 92
- see also* Dosimeters
- U.S. European Command (EUCOM) Chernobyl Task Force, 238-239
  - address, 275
  
- Vaccination. *See* Active vaccination
- Vinca, Yugoslavia, radiation accident at, 30-31
- Vitamin A, 251, 256
- Vitamin E, 251, 256
  
- Walter Reed Army Institute of Research (WRAIR), 250, 254
  - address, 275
- Weapon yield, 5
- Whole-body radionuclide determination, 97
- Wound closure, 79
  - and immunosuppression, 79
  - and systemic sepsis, 79
- WR-2721 (ethiofos), 133, 250-254, 264
- WRAIR. *See* Walter Reed Army Institute of Research
- WRAIR sulfur compounds, 133, 250-254
  
- X radiation, 172
  - and cancer induction, 179
  - and cancer treatment, 179
  - exposure to, 177
  - and lymphocytes, 94
  - see also* Radiotherapy
- X rays, 2, 246
  - plasma as source of, 5
- Xeroderma pigmentosum, 182, 202
  
- Yield. *See* Weapon yield
  
- Zacopride (5-HT<sub>3</sub>-receptor blocker)
  - as antiemetic, 133
- Zinc protoporphyrin (ZPP), 86, 87, 97
- ZPP. *See* Zinc protoporphyrin
- Zymosan, 259-260